Johnson & Johnson (NYSE: JNJ) Shares Acquired by Salvus Wealth Management LLC


Salvus Wealth Management LLC increased its holdings in Johnson & Johnson (NYSE: JNJ – Get Rating) by 2.7% in the first quarter, HoldingsChannel.com reports. The institutional investor owned 5,876 shares of the company’s stock after purchasing an additional 157 shares during the quarter. Salvus Wealth Management LLC’s holdings in Johnson & Johnson were worth $ 1,041,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also modified their holdings of the stock. Magnolia Capital Management Ltd. boosted its stake in Johnson & Johnson by 0.5% during the 1st quarter. Magnolia Capital Management Ltd. now owns 11,162 shares of the company’s stock valued at $ 1,978,000 after purchasing an additional 55 shares in the last quarter. Capital Investment Counsel Inc boosted its stake in Johnson & Johnson by 0.8% during the 4th quarter. Capital Investment Counsel Inc now owns 7,796 shares of the company’s stock valued at $ 1,334,000 after purchasing an additional 59 shares in the last quarter. Beaton Management Co. Inc. boosted its stake in Johnson & Johnson by 0.3% during the 4th quarter. Beaton Management Co. Inc. now owns 22,250 shares of the company’s stock valued at $ 3,806,000 after purchasing an additional 60 shares in the last quarter. Corsicana & Co. boosted its stake in Johnson & Johnson by 0.4% during the 1st quarter. Corsicana & Co. now owns 15,553 shares of the company’s stock valued at $ 2,756,000 after purchasing an additional 60 shares in the last quarter. Finally, Iron Horse Wealth Management LLC boosted its stake in Johnson & Johnson by 29.9% during the 4th quarter. Iron Horse Wealth Management LLC now owns 265 shares of the company’s stock valued at $ 45,000 after purchasing an additional 61 shares in the last quarter. 68.78% of the stock is owned by institutional investors and hedge funds.

Several equities research analysts have recently weighed in on JNJ shares. Citigroup reduced their price objective on Johnson & Johnson from $ 210.00 to $ 205.00 in a research note on Tuesday, May 17th. Raymond James raised their price objective on Johnson & Johnson from $ 195.00 to $ 196.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 20th. Sanford C. Bernstein lowered Johnson & Johnson from an “outperform” rating to a “market perform” rating and raised their price objective for the stock from $ 180.00 to $ 183.00 in a research note on Wednesday, March 16th. Bank of America started coverage on Johnson & Johnson in a report on Wednesday, March 2nd. They issued a “neutral” rating for the company. Finally, The Goldman Sachs Group increased their target price on Johnson & Johnson from $ 163.00 to $ 181.00 and gave the company a “neutral” rating in a report on Tuesday, April 12th. Four analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $ 190.50.

In other Johnson & Johnson news, insider William Hait sold 29,699 shares of the firm’s stock in a transaction dated Thursday, April 21st. The stock was sold at an average price of $ 183.58, for a total transaction of $ 5,452,142.42. Following the transaction, the insider now directly owns 80,236 shares in the company, valued at $ 14,729,724.88. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CAO Robert J. Decker sold 8,462 shares of the firm’s stock in a transaction dated Thursday, May 26th. The shares were sold at an average price of $ 180.00, for a total value of $ 1,523,160.00. Following the transaction, the chief accounting officer now owns 15,473 shares in the company, valued at $ 2,785,140. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 78,161 shares of company stock worth $ 13,895,302. Corporate insiders own 0.35% of the company’s stock.

Shares of NYSE: JNJ opened at $ 179.66 on Friday. The company has a current ratio of 1.39, a quick ratio of 1.14 and a debt-to-equity ratio of 0.39. Johnson & Johnson has a 1 year low of $ 155.72 and a 1 year high of $ 186.69. The business has a fifty day simple moving average of $ 177.65 and a 200 day simple moving average of $ 173.20. The firm has a market cap of $ 472.76 billion, a price-to-earnings ratio of 24.21, a P / E / G ratio of 3.42 and a beta of 0.66.

Johnson & Johnson (NYSE: JNJ – Get Rating) last announced its quarterly earnings data on Tuesday, April 19th. The company reported $ 2.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $ 2.60 by $ 0.07. Johnson & Johnson had a return on equity of 36.59% and a net margin of 20.90%. The business had revenue of $ 23.43 billion during the quarter, compared to analyst estimates of $ 23.62 billion. During the same period last year, the company earned $ 2.59 earnings per share. Johnson & Johnson’s quarterly revenue was up 5.0% compared to the same quarter last year. On average, sell-side analysts forecast that Johnson & Johnson will post 10.23 EPS for the current year.

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 7th. Shareholders of record on Tuesday, May 24th were issued a dividend of $ 1.13 per share. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $ 1.06. This represents a $ 4.52 annualized dividend and a yield of 2.52%. The ex-dividend date of this dividend was Monday, May 23rd. Johnson & Johnson’s dividend payout ratio (DPR) is 60.92%.

About Johnson & Johnson (Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health / beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Articles

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE: JNJ – Get Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE: JNJ)



Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.

.

Leave a Reply

Your email address will not be published.

Back to top button
AGADIR-GROUP